Literature DB >> 10936092

Defining CTL-induced pathology: implications for HIV.

D Wodarz1, D C Krakauer.   

Abstract

The relationship between virus and host cells is multifactorial and nonlinear. This indicates that the effect of an immune response on infection can lead to several different outcomes. These include severe immunopathology. We seek to define properties of CTL-induced pathology in viral infections and examine the implications for HIV disease progression. We find that CTL-induced pathology is observed if the rate of viral replication is fast relative to the CTL responsiveness of the host. Theoretical predictions are consistent with empirical data on LCMV infection. These conditions are also sufficient to induce pathology in HIV infection. However, the absence of HIV-specific CTL can result in an equivalent depletion of the CD4 T cell pool as a consequence of the short life span of activated T cells. A mathematical model describing the evolution of HIV coreceptor usage in the context of lytic and nonlytic CD8 cell responses might account for the relatively long time span required to result in disease. Viral evolution toward parameter ranges allowing CTL-induced pathology is difficult to achieve. It requires the emergence of fast viral replication together with escape from nonlytic CTL responses. However, according to the model, fast viral replication can result in the evolution of virus strains that are susceptible to chemokine-mediated inhibition of viral replication. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936092     DOI: 10.1006/viro.2000.0399

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  Pathology during acute infections: contributions of intracellular pathogens and the CTL response.

Authors:  Vitaly V Ganusov; Rustom Antia
Journal:  Biol Lett       Date:  2005-06-22       Impact factor: 3.703

2.  Evolution of parasite virulence when host responses cause disease.

Authors:  Troy Day; Andrea L Graham; Andrew F Read
Journal:  Proc Biol Sci       Date:  2007-11-07       Impact factor: 5.349

3.  Sharing the burden: antigen transport and firebreaks in immune responses.

Authors:  Andreas Handel; Andrew Yates; Sergei S Pilyugin; Rustom Antia
Journal:  J R Soc Interface       Date:  2008-08-15       Impact factor: 4.118

Review 4.  Modeling T cell responses to antigenic challenge.

Authors:  Dominik Wodarz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-01       Impact factor: 2.745

5.  Demyelinating and nondemyelinating strains of mouse hepatitis virus differ in their neural cell tropism.

Authors:  Jayasri Das Sarma; Kathryn Iacono; Lilli Gard; Ryan Marek; Lawrence C Kenyon; Michael Koval; Susan R Weiss
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

6.  A mechanism of virus-induced demyelination.

Authors:  Jayasri Das Sarma
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-06-21

7.  Predicting the impact of CD8+ T cell polyfunctionality on HIV disease progression.

Authors:  Frederik Graw; Roland R Regoes
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

8.  Immunity and protection by live attenuated HIV/SIV vaccines.

Authors:  Dominik Wodarz
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

9.  Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys.

Authors:  Ronald S Veazey; Paula M Acierno; Kimberly J McEvers; Susanne H C Baumeister; Gabriel J Foster; Melisa D Rett; Michael H Newberg; Marcelo J Kuroda; Kenneth Williams; Eun-Young Kim; Steven M Wolinsky; E Peter Rieber; Michael Piatak; Jeffrey D Lifson; David C Montefiori; Charles R Brown; Vanessa M Hirsch; Jörn E Schmitz
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

10.  Human immunodeficiency virus evolution towards reduced replicative fitness in vivo and the development of AIDS.

Authors:  Dominik Wodarz; David N Levy
Journal:  Proc Biol Sci       Date:  2007-10-07       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.